Meta-Analysis of Neoadjuvant Immunochemotherapy for Potentially Resectable NSCLC

A meta-analysis of 34 studies involving 1,885 patients with stage IIB–IIIB non-small cell lung cancer (NSCLC). The study, authored by Feng Wu, was uploaded to figshare on 2026-05-07 and pools data on surgical resection rates, pathological response, and adverse events from research published up to December 2025.

Use Cases

• Benchmarking pathological complete response (pCR) rates for neoadjuvant immunochemotherapy based on the reported pooled rate of 35.9%.
• Estimating surgical feasibility and complication rates based on the reported 76.0% resection rate and 8.0% surgical complication rate.
• Assessing treatment safety profiles based on the reported 9.0% incidence of grade ≥3 adverse events.
• Informing power calculations for future randomized controlled trials based on the pooled effect sizes and confidence intervals provided.

Strengths

• Includes data from 1,885 patients across 34 studies, providing a substantial sample for analysis.
• Reports specific, pooled outcome metrics with 95% confidence intervals, such as a 35.9% pCR rate and a 76.0% surgical resection rate.
• Follows PRISMA-NMA guidelines and includes sensitivity analyses and bias assessments, suggesting a structured methodology.

Limitations

• Row count and column-level documentation are absent; field semantics must be inferred after download.
• The underlying data is a single-arm meta-analysis; the description notes a lack of comparator data, limiting causal inference.
• The dataset is a 344.3 KB DOCX file, which suggests a limited scope, likely containing summary tables rather than raw patient-level data.

Provenance

Source

Feng Wu via figshare.

Collection Method

Systematic review and single-arm meta-analysis of studies from PubMed, Embase, and Cochrane up to 9 December 2025.

Time Range

Studies included up to December 2025.

Freshness

Last updated 2026-05-07 04:45:42; freshness should be verified.